Because Expertise Matters
Join Cyberounds®, an online education community for health professionals Sign Up

Log In

CME

New Therapies for Type 2 Diabetes

The pharmacological management of type 2 diabetes is rapidly evolving.
CME credit is no longer available for this conference.

Course Authors

In the past three years, Dr. Ipp has received grant/research support from Pfizer, Inc., R.W. Johnson, and Novo-Nordisk. He has served as a consultant for Novo-Nordisk, SmithKline Beecham Pharmaceutical and Hoechst Marion Roussel. Dr Ipp has also served on the Speakers' Bureau for Novo-Nordisk.

This activity is made possible by an unrestricted educational grant from the Novartis Foundation for Gerontology.

Estimated course time: 1 hour(s).

Albert Einstein College of Medicine – Montefiore Medical Center designates this enduring material activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

In support of improving patient care, this activity has been planned and implemented by Albert Einstein College of Medicine-Montefiore Medical Center and InterMDnet. Albert Einstein College of Medicine – Montefiore Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

 
Learning Objectives

Upon completion of this Cyberounds®, you should be able to:

  • Discuss the range of new medications available for treatment of type 2 diabetes

  • Describe the mechanism of action of these medications, where it is known

  • Discuss the use of combination therapies.

 

TERMS AND CONDITIONS

This conference may include discussion of commercial products and services.

The opinions expressed herein are those of the authors and do not necessarily represent the views of the sponsor or its publisher. Please review complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings and adverse effects before administering pharmacologic therapy to patients.

 

Please click below to accept the terms of this CME activity

Courses You Might Like

The Treatment and Management of Type 1 Diabetes Mellitus: 2019 Update

New and modified treatment options for the TIDM patient.
Authors: Sheryl Merkin, M.S., F.N.P., C.D.E., Sharon Movsas, M.S., R.D., C.D.E. and Joel Zonszein, M.D., C.D.E.
Estimated Time: 1 Hour
More

Acromegaly

Acromegaly is a clinical syndrome occurring as a consequence of growth hormone excess during adult life, most often from a pituitary adenoma.
Authors: Nicholas A. Tritos, M.D., D.Sc.
Estimated Time: 1 Hour
More

Progestins and the Brain

Progestin therapy affects every major organ system including the brain.
Authors: Muye Zhu, B.S., and Roberta Diaz Brinton, Ph.D.
Estimated Time: 1 Hour
More

Lipoproteins and Apolipoproteins In The Brain

The brain is an exceptionally lipid-rich organ.
Authors: Simona Vuletic, M.D.
Estimated Time: 1 Hour
More

Neuropathic Complications of Diabetes

The complications of diabetes mellitus that affect the nervous system belong to the category of metabolic neuropathies.
Authors: John W. Wiley, M.D., and Roberto Towns, Ph.D.
Estimated Time: 1 Hour
More

Glucose Sensing in the Central Nervous System

The brain is an obligate glucose consumer and critically dependent on glucose supply for normal function.
Authors: Kelly A. Diggs-Andrews, B.S., Julie M. Silverstein, M.D., and Simon J. Fisher, M.D., Ph.D.
Estimated Time: 1 Hour
More